Kevser Sevim - Quotient Sciences

Kevser Sevim

Senior Modelling and Simulation Research Fellow

About

Dr. Kevser Sevim is a Senior Research Fellow who brings her expertise to the dynamic Modelling and Simulation (M&S) team at Quotient Sciences. Her primary focus revolves around advancing the understanding of ADME (absorption, distribution, metabolism, and excretion) and biopharmaceutics in compound design and selection, utilizing a range of M&S data analysis packages including GastroPlus and Phoenix WinNonlin.

Over her five years of experience in this role, Kevser has played a key role in accelerating drug development and manufacturing through the application of in-silico PBPK (physiologically-based pharmacokinetic) modeling. Her contributions provide valuable scientific support across both discovery and development programs.

Kevser holds a PhD from the University of Leicester, UK, where she specialized in the modeling of drug release from biodegradable and bioerodible polymers. Before her doctoral studies, she earned a Bachelor of Science degree in Chemical Engineering from Gazi University, Turkey.

Hexagons on blue gradient background with Quotient Sciences logo
Modeling and Simulation, Kevser Sevim

Scientific Poster Spotlight: Qualification of GastroPlus® PBPK Modeling Software to Support Decision Making in Clinical Development

Read More

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, commercial manufacturing, Dr. Helen Baker, Dr. Richard Castledine Dr. Helen Baker and Dr. Richard Castledine contribute to Pharmaceutical Technology's 'Poor API Quality Threatens a Healthy Supply' By: Dr. Helen Baker and Dr. Richard Castledine
Read More
News & Announcements, Articles & Publications, Thierry Van Nieuwenhove Thierry Van Nieuwenhove on the Future of CDMO Partnerships By: Thierry Van Nieuwenhove
Read More
News & Announcements, Translational Pharmaceutics®, Articles & Publications BioPharm International interviews Helen Baker about how Quotient Sciences is optimizing drug development
Read More
Get in touch
Humanity can't afford to wait, so neither can we.